1 of the major un met need for patients with amyloidosis is earlier diagnosis. Currently 30% of patients succumb to the disease within the 1st year following diagnosis. This is because the diagnosis is delayed due to failure recognize.
One of the most common cytogenetic abnormalities in myeloma is one of the most widely debated and poorly understood. We have summarized the literature of this mysterious genomic aberration and call for standardization as a key to understanding the significance of +1q and improving patient outcomes.
Digital Display Precision Predictor (DDPP) is potentially a new global biomarker model that can apply to any type of drug alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activites described below. To learn more about how these trackers help us